Gene Biotherapeutics (Gene Biotherapeutics) Total Assets : $0.57 Mil (As of Dec. 2020)

View and export this data going back to . Start your Free Trial

What is Gene Biotherapeutics Total Assets?

Gene Biotherapeutics's Total Assets for the quarter that ended in Dec. 2020 was $0.57 Mil.

Total Assets is connected with ROA %. Gene Biotherapeutics's annualized ROA % for the quarter that ended in Dec. 2020 was -229.83%. Total Assets is also linked to Revenue through Asset Turnover. Gene Biotherapeutics's Asset Turnover for the quarter that ended in Dec. 2020 was 0.00.

Gene Biotherapeutics Total Assets Historical Data

The historical data trend for Gene Biotherapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gene Biotherapeutics Total Assets Chart

Gene Biotherapeutics Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Total Assets

Get a 7-Day Free Trial

1.11

0.21

0.16

0.04

0.57

Gene Biotherapeutics Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Dec17	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20
Total Assets	Get a 7-Day Free Trial															0.04	0.13	1.34	0.98	0.57

Gene Biotherapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Gene Biotherapeutics's Total Assets for the fiscal year that ended in Dec. 2020 is calculated as

Total Assets	=	Total Equity (A: Dec. 2020 )	+	Total Liabilities (A: Dec. 2020 )
	=	-4.568	+	5.135
	=	0.57

Gene Biotherapeutics's Total Assets for the quarter that ended in Dec. 2020 is calculated as

Total Assets	=	Total Equity (Q: Dec. 2020 )	+	Total Liabilities (Q: Dec. 2020 )
	=	-4.568	+	5.135
	=	0.57

Gene Biotherapeutics (OTCPK:CRXM) Total Assets Explanation

Total Assets is connected with ROA %.

Gene Biotherapeutics's annualized ROA % for the quarter that ended in Dec. 2020 is

ROA %	=	Net Income (Q: Dec. 2020 )	/	( (Total Assets (Q: Sep. 2020 )	+	Total Assets (Q: Dec. 2020 ))	/ count )
	=	-1.772	/	( (0.975	+	0.567)	/ 2 )
	=	-1.772	/	0.771
	=	-229.83 %

Note: The Net Income data used here is four times the quarterly (Dec. 2020) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Gene Biotherapeutics's Asset Turnover for the quarter that ended in Dec. 2020 is

	Asset Turnover
=	Revenue (Q: Dec. 2020 )	/	( (Total Assets (Q: Sep. 2020 )	+	Total Assets (Q: Dec. 2020 ))	/ count )
=	0	/	( (0.975	+	0.567)	/ 2 )
=	0	/	0.771
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Gene Biotherapeutics Total Assets Related Terms

Thank you for viewing the detailed overview of Gene Biotherapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Gene Biotherapeutics (Gene Biotherapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gene Biotherapeutics Inc (OTCPK:CRXM) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

11230 Sorrento Valley Road, Suite 220, San Diego, CA, USA, 92121

Website

https://www.genebiotherapeutics.com

Gene Biotherapeutics Inc is a clinical stage biotechnology company focused on pre-clinical, clinical, and commercialization of angiogenic gene therapy biotherapeutics for strategic niche markets primarily for the treatment of cardiovascular disease. The company's lead product candidate Generx is an angiogenic gene therapy product candidate designed for medical revascularization for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease.

Executives

Andrew M Leitch	director	6615 CALLE PONTE BELLA, RANCHO SANTA FE CA 92091
Murray H Hutchison	director	C/O CADIZ INC., 550 SOUTH HOPE STREET, 2850, LOS ANGELES CA 90071
Dennis Mulroy	officer: Chief Financial Officer
Ronald I Simon	other: Former Director	485 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10022
Robert N Weingarten	director, officer: PRESIDENT and CFO	5439 LOCKHURST DRIVE, WOODLAND HILLS CA 91367

Gene Biotherapeutics (Gene Biotherapeutics) Headlines

From GuruFocus

Baron Funds Comments on CarMax Inc.

By Holly LaFon • 02-06-2013

Cardium Therapeutics Inc Reports Operating Results (10-Q)

By gurufocus 10qk • 05-10-2010

Cardium Therapeutics Inc Reports Operating Results (10-Q)

By gurufocus 10qk • 11-09-2010

Gene Biotherapeutics Announces Sale Of Excellagen Technology Platform; Retains Commercialization Rights For Greater China And Russian Federation

By PRNewswire PRNewswire • 09-05-2018